Erratum: Corrigendum to “Extended-release naltrexone opioid treatment at jail reentry (XOR)” (Contemporary Clinical Trials (2016) 51 (96) (S1551714416300593) (10.1016/j.cct.2016.05.002))

Ryan D. McDonald, Babak Tofighi, Eugene Laska, Keith Goldfeld, Wanda Bonilla, Mara Flannery, Nadina Santana-Correa, Christopher W. Johnson, Neil Leibowitz, John Rotrosen, Marc Gourevitch, Joshua Lee

Research output: Contribution to journalComment/debate

Abstract

We mistakenly stated that a modified Composite International Diagnostic Interview 2 (CIDI-2) will be used to assess opioid use disorder. Instead, we will use select items from the World Mental Health Composite International Diagnostic Interview [WMH-CIDI] (http://www.hcp.med.harvard.edu/wmhcidi/index.php) for that purpose. Page 59 under Section 2.4. Study population and inclusion/exclusion criteria should read “Eligible participants across all three arms are adults currently incarcerated in a New York City jail with a known release date, meet criteria for DSM-V current opioid use disorder based on a modified World Mental Health Composite International Diagnostic Interview (modified WMH-CIDI), an updated version of the CIDI-2 for Substance Use Disorders [21], and are of general good health.” In Table 2, “CIDI II DSM-5 checklist” should read “modified WMH-CIDI.” On page 62, the third paragraph under the Section 5.2 Secondary Outcomes should indicate use of the modified WMH-CIDI rather than the modified CIDI-2.

Original languageEnglish (US)
Pages (from-to)96
Number of pages1
JournalContemporary Clinical Trials
Volume51
DOIs
StatePublished - Nov 1 2016

Fingerprint

Naltrexone
Opioid Analgesics
Clinical Trials
Interviews
Mental Health
corrigendum
Checklist
Diagnostic and Statistical Manual of Mental Disorders
Substance-Related Disorders
Global Health
Health
Population

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Erratum : Corrigendum to “Extended-release naltrexone opioid treatment at jail reentry (XOR)” (Contemporary Clinical Trials (2016) 51 (96) (S1551714416300593) (10.1016/j.cct.2016.05.002)). / McDonald, Ryan D.; Tofighi, Babak; Laska, Eugene; Goldfeld, Keith; Bonilla, Wanda; Flannery, Mara; Santana-Correa, Nadina; Johnson, Christopher W.; Leibowitz, Neil; Rotrosen, John; Gourevitch, Marc; Lee, Joshua.

In: Contemporary Clinical Trials, Vol. 51, 01.11.2016, p. 96.

Research output: Contribution to journalComment/debate

McDonald, Ryan D. ; Tofighi, Babak ; Laska, Eugene ; Goldfeld, Keith ; Bonilla, Wanda ; Flannery, Mara ; Santana-Correa, Nadina ; Johnson, Christopher W. ; Leibowitz, Neil ; Rotrosen, John ; Gourevitch, Marc ; Lee, Joshua. / Erratum : Corrigendum to “Extended-release naltrexone opioid treatment at jail reentry (XOR)” (Contemporary Clinical Trials (2016) 51 (96) (S1551714416300593) (10.1016/j.cct.2016.05.002)). In: Contemporary Clinical Trials. 2016 ; Vol. 51. pp. 96.
@article{728e8f9ddc5f4c279da2605a94306a3d,
title = "Erratum: Corrigendum to “Extended-release naltrexone opioid treatment at jail reentry (XOR)” (Contemporary Clinical Trials (2016) 51 (96) (S1551714416300593) (10.1016/j.cct.2016.05.002))",
abstract = "We mistakenly stated that a modified Composite International Diagnostic Interview 2 (CIDI-2) will be used to assess opioid use disorder. Instead, we will use select items from the World Mental Health Composite International Diagnostic Interview [WMH-CIDI] (http://www.hcp.med.harvard.edu/wmhcidi/index.php) for that purpose. Page 59 under Section 2.4. Study population and inclusion/exclusion criteria should read “Eligible participants across all three arms are adults currently incarcerated in a New York City jail with a known release date, meet criteria for DSM-V current opioid use disorder based on a modified World Mental Health Composite International Diagnostic Interview (modified WMH-CIDI), an updated version of the CIDI-2 for Substance Use Disorders [21], and are of general good health.” In Table 2, “CIDI II DSM-5 checklist” should read “modified WMH-CIDI.” On page 62, the third paragraph under the Section 5.2 Secondary Outcomes should indicate use of the modified WMH-CIDI rather than the modified CIDI-2.",
author = "McDonald, {Ryan D.} and Babak Tofighi and Eugene Laska and Keith Goldfeld and Wanda Bonilla and Mara Flannery and Nadina Santana-Correa and Johnson, {Christopher W.} and Neil Leibowitz and John Rotrosen and Marc Gourevitch and Joshua Lee",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.cct.2016.09.009",
language = "English (US)",
volume = "51",
pages = "96",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Erratum

T2 - Corrigendum to “Extended-release naltrexone opioid treatment at jail reentry (XOR)” (Contemporary Clinical Trials (2016) 51 (96) (S1551714416300593) (10.1016/j.cct.2016.05.002))

AU - McDonald, Ryan D.

AU - Tofighi, Babak

AU - Laska, Eugene

AU - Goldfeld, Keith

AU - Bonilla, Wanda

AU - Flannery, Mara

AU - Santana-Correa, Nadina

AU - Johnson, Christopher W.

AU - Leibowitz, Neil

AU - Rotrosen, John

AU - Gourevitch, Marc

AU - Lee, Joshua

PY - 2016/11/1

Y1 - 2016/11/1

N2 - We mistakenly stated that a modified Composite International Diagnostic Interview 2 (CIDI-2) will be used to assess opioid use disorder. Instead, we will use select items from the World Mental Health Composite International Diagnostic Interview [WMH-CIDI] (http://www.hcp.med.harvard.edu/wmhcidi/index.php) for that purpose. Page 59 under Section 2.4. Study population and inclusion/exclusion criteria should read “Eligible participants across all three arms are adults currently incarcerated in a New York City jail with a known release date, meet criteria for DSM-V current opioid use disorder based on a modified World Mental Health Composite International Diagnostic Interview (modified WMH-CIDI), an updated version of the CIDI-2 for Substance Use Disorders [21], and are of general good health.” In Table 2, “CIDI II DSM-5 checklist” should read “modified WMH-CIDI.” On page 62, the third paragraph under the Section 5.2 Secondary Outcomes should indicate use of the modified WMH-CIDI rather than the modified CIDI-2.

AB - We mistakenly stated that a modified Composite International Diagnostic Interview 2 (CIDI-2) will be used to assess opioid use disorder. Instead, we will use select items from the World Mental Health Composite International Diagnostic Interview [WMH-CIDI] (http://www.hcp.med.harvard.edu/wmhcidi/index.php) for that purpose. Page 59 under Section 2.4. Study population and inclusion/exclusion criteria should read “Eligible participants across all three arms are adults currently incarcerated in a New York City jail with a known release date, meet criteria for DSM-V current opioid use disorder based on a modified World Mental Health Composite International Diagnostic Interview (modified WMH-CIDI), an updated version of the CIDI-2 for Substance Use Disorders [21], and are of general good health.” In Table 2, “CIDI II DSM-5 checklist” should read “modified WMH-CIDI.” On page 62, the third paragraph under the Section 5.2 Secondary Outcomes should indicate use of the modified WMH-CIDI rather than the modified CIDI-2.

UR - http://www.scopus.com/inward/record.url?scp=84995549948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995549948&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2016.09.009

DO - 10.1016/j.cct.2016.09.009

M3 - Comment/debate

VL - 51

SP - 96

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

ER -